




[This Photo](#) by Unknown Author is licensed under [CC BY-SA-NC](#)

Nivolumab improves overall survival and objective response rate versus everolimus

OUTLINE



Introduction



Methods



Results




Conclusion



Future Recommendations

Therapies approved in Japan for advanced renal cell carcinoma



Phase 3 CheckMate 025 study

	Nivolumab	Everolimus
Overall Survival (OS)	25.0 months	19.6 months
Objective Response Rate (ORR)	25%	5%



Methods



Patients randomized 1:1 and received either nivolumab or everolimus

**Nivolumab 3mg/kg IV
over 60 min every 2
weeks**

**Everolimus 10 mg
tablet orally once a day**

Endpoints


Overall survival


Objective response rate

Progression-free survival

Assessments

Computed tomography or magnetic resonance imaging







Results




Overall survival with 2 years of follow-up



Objective response rate






Conclusion



After > 2 years of follow up



Nivolumab



Everolimus



Future Recommendations

To correct limitations



Should nivolumab be used in previously treated patients in Japan?